One of DMSG's main purposes has been to establish and run a nationally rooted biobank, which is suited for research and tied to the clinical data that are reported to the national myeloma database (LMDB).

Simultaneously with this process, Danish CancerBiobank (DCB) was established in 2009. From the beginning, DCB was established to freeze the solid cancer types. DMSG subsequently contributed in a collective hematological effort to become a part of DCB, and thereby secure the opportunity for freezing the liquid cancers in blood and bone marrow.

The collective effort proved to be successful. In 2012, the hematological cancer diseases became an integrated part of DCB. This has secured prospective financing, and structure for compilation of biological material of myeloma and associated diseases.